Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 762
Filter
1.
Ann R Coll Surg Engl ; 103(10): e338-e340, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34448403

ABSTRACT

A 62-year old woman presented with a 1-month history of left otalgia, facial palsy and hearing loss. She had a background of non-insulin-dependent diabetes mellitus and stage 2 endometrial adenocarcinoma, treated 18 months ago. Computed tomography scan showed erosion of the skull base and temporal bone. She was referred to the otolaryngology team with a diagnosis of necrotising otitis externa. On clinical examination, there was an exophytic, necrotic lesion in the ear canal arising from the posterior canal wall. A subsequent magnetic resonance imaging scan showed a lesion located in the left jugular foramen extending into the middle ear, with characteristics consistent with a glomus jugulo-tympanicum. Interestingly, histology of the lesion showed malignant cells with immunohistochemical staining suggestive of an adenocarcinoma. This is the first reported case of metastatic endometrial carcinoma involving the jugular foramen and temporal bone. Although a diagnosis is rare, it is important to consider it when other differential diagnoses are not fitting. Imaging should always be interpreted with caution, correlating to the clinical findings.


Subject(s)
Adenocarcinoma/pathology , Endometrial Neoplasms/pathology , Neoplasm Recurrence, Local/pathology , Skull Base Neoplasms/secondary , Skull Neoplasms/secondary , Temporal Bone , Female , Humans , Magnetic Resonance Imaging , Middle Aged , Skull Base Neoplasms/diagnostic imaging , Skull Neoplasms/diagnostic imaging , Temporal Bone/diagnostic imaging , Tomography, X-Ray Computed
3.
Neurosurg Rev ; 44(1): 289-300, 2021 Feb.
Article in English | MEDLINE | ID: mdl-32078084

ABSTRACT

"Benign" metastatic leiomyomas (BML) are indolently growing metastatic tumors which mostly associate with uterine leiomyomas in women in reproductive ages. The reason to define these lesions as "benign" despite metastasis is their pathological features with low mitotic counts, lack of or minimal nuclear atypia, pseudocyst formation, and coagulative necrosis unlike leiomyosarcomas. Despite lack of pathological malignant features, they may cause significant morbidity and even mortality. Here, we describe a BML case with metastases to vertebrae and skull bones. Vertebral and skull metastases of BMLs were very rarely reported. In treatment of these tumors, hysterectomy and GnRH modifier treatments are widely employed. GnRH agonists act by desensitization and downregulation of the GnRH receptors, while GnRH antagonists act via the canonical competitive blockage. These treatments reduce FSH and LH levels, thereby reducing the systemic levels of sex steroids which stimulate leiomyoma growth. However, leiomyomas inherently harbor aromatase activity and synthesize their own estrogen; hence, treatment with systemic estrogen antagonists may provide better tumor control. Another important factor in BML pathogenesis is progesterone, and both progesterone receptor antagonists and high-dose progesterone receptor agonists may reduce BML growth. Following surgical treatment of the calvarial mass and radiotherapy of the vertebral metastatic foci, our BML case was successfully managed with hysterectomy and anastrozole treatment. Higher awareness of BML cases and their molecular endocrinological features in the neurosurgical community may pave to develop better strategies for treatment of these tumors causing high morbidity.


Subject(s)
Leiomyoma/diagnostic imaging , Progesterone/antagonists & inhibitors , Skull Neoplasms/therapy , Spinal Neoplasms/diagnostic imaging , Uterine Neoplasms/diagnostic imaging , Adult , Female , Hormone Antagonists/pharmacology , Hormone Antagonists/therapeutic use , Humans , Leiomyoma/blood , Leiomyoma/therapy , Progesterone/blood , Skull Neoplasms/blood , Skull Neoplasms/diagnostic imaging , Skull Neoplasms/secondary , Spinal Neoplasms/blood , Spinal Neoplasms/secondary , Spinal Neoplasms/therapy , Uterine Neoplasms/blood , Uterine Neoplasms/therapy
4.
Clin Nucl Med ; 46(1): 63-65, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33181755

ABSTRACT

A 74-year-old man with prostate adenocarcinoma (Gleason 7) was referred for Ga-prostate-specific membrane antigen (PSMA-HBED-CC) PET/CT scan for staging. Findings confirmed the prostate malignancy and demonstrated a solitary metastasis in the left skull base, with no evidence of regional or distant metastasis elsewhere. Solitary base of the skull metastasis may be subtle and easily overlooked, highlighting the need for thorough evaluation of the region.


Subject(s)
Adenocarcinoma/pathology , Membrane Glycoproteins , Organometallic Compounds , Positron Emission Tomography Computed Tomography , Prostatic Neoplasms/pathology , Skull Neoplasms/diagnostic imaging , Skull Neoplasms/secondary , Aged , Gallium Isotopes , Gallium Radioisotopes , Humans , Male
5.
J Cancer Res Ther ; 16(4): 935-937, 2020.
Article in English | MEDLINE | ID: mdl-32930146

ABSTRACT

Bone metastasis from lung primary is not uncommon and about one-third of bone metastases originate from lung. However, skull bone metastasis is uncommon from lung carcinoma. Metastasis to skull bone and scalp as an initial presentation of lung carcinoma is a very rare phenomenon. We have diagnosed a case of calvarial metastasis with scalp swelling as an initial presentation of adenocarcinoma of lung by fine-needle aspiration cytology in an aged female. Radiologically, it was suggested as tuberculous lesion but cytology gave the correct diagnosis. Here, we present a rare case of calvarial metastasis as a presentation of adenocarcinoma of lung in an elderly female.


Subject(s)
Adenocarcinoma of Lung/pathology , Lung Neoplasms/pathology , Scalp/pathology , Skull Neoplasms/secondary , Adenocarcinoma of Lung/surgery , Aged , Cytodiagnosis/methods , Female , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/surgery , Prognosis , Scalp/surgery , Skull Neoplasms/diagnosis , Skull Neoplasms/surgery
8.
World Neurosurg ; 138: e17-e25, 2020 06.
Article in English | MEDLINE | ID: mdl-32142948

ABSTRACT

BACKGROUND: Eccrine carcinoma involvement of the central nervous system (CNS) is exceedingly rare. The prognosis and response to treatment of this pathology remain poorly characterized. METHODS: A retrospective case series and literature review were conducted. RESULTS: CNS-invading eccrine carcinoma was diagnosed in 3 patients (2 male and 1 female; age range, 60-79 years), including 2 cases of brain metastases and 1 case of brain-invading skull metastasis with subsequent spinal metastasis. The interval from primary tumor to CNS invasion was 18-51 months. All patients received multimodal therapy following diagnosis of CNS involvement. One patient who harbored a NOTCH1 mutation demonstrated a durable oncologic response after treatment with the immune checkpoint inhibitor pembrolizumab and lived 39 months after CNS invasion. The other 2 patients were discharged to hospice care within 1 month after the diagnosis of eccrine carcinoma brain metastasis. Including this case series, 23 cases of eccrine carcinoma invasion or metastasis to the CNS have been reported, with survival after diagnosis of CNS involvement ranging from a few weeks to 4 years. CONCLUSIONS: We present 3 cases of eccrine carcinoma metastatic to the CNS, including the first reported case to our knowledge of eccrine carcinoma treated with immunotherapy. This case, harboring a NOTCH1 mutation, demonstrated the longest durable oncologic response reported in this rare disease. Genomic and molecular testing may play increasingly important roles in the evaluation of these metastases.


Subject(s)
Brain Neoplasms/secondary , Carcinoma/secondary , Eccrine Glands , Head and Neck Neoplasms/pathology , Skull Neoplasms/secondary , Spinal Neoplasms/secondary , Sweat Gland Neoplasms/pathology , Abdominal Wall , Aged , Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents, Immunological/therapeutic use , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/drug therapy , Brain Neoplasms/genetics , Carcinoma/drug therapy , Carcinoma/genetics , Carcinoma, Ductal/secondary , Female , Humans , Male , Middle Aged , Neoplasm Invasiveness , Receptor, Notch1/genetics , Scalp , Skull Neoplasms/diagnostic imaging , Spinal Neoplasms/diagnostic imaging
10.
World Neurosurg ; 137: 276-280, 2020 05.
Article in English | MEDLINE | ID: mdl-32084613

ABSTRACT

BACKGROUND: Patients with isolated occipital condyle lesions concerning for metastases rarely undergo surgical biopsies and are more commonly treated with empirical radiation with or without chemotherapy. This is likely related to the morbidity associated with open condylar approaches and the importance of surrounding structures. We present a minimally invasive technique to approach the occipital condyle using a tubular dilating retractor system. CASE DESCRIPTION: A 38-year-old woman with medical history of breast cancer presented with a 2-month history of headache localizing to the right occipital area and right tongue deviation. Magnetic resonance imaging revealed a heterogeneously enhancing mass within the right occipital condyle. The patient was brought into the operating room and placed in prone position. A 2-cm paramedian incision was made on the right approximately 2.5 cm off midline at the level of C1. Sequential dilation using a tubular retractor system was performed under fluoroscopic guidance. Once the condylar cortex was identified and entered, the tumor was immediately visualized and resected. Operative time was 65 minutes and estimated blood loss was 5 mL. The patient was discharged to home on postoperative day 1. CONCLUSIONS: This report, to our knowledge, presents the first case of a minimally invasive tubular retractor system-based approach for biopsy and resection of an occipital condylar metastasis causing occipital condyle syndrome. This approach allows for tissue diagnosis to precisely dictate medical management and minimizes the morbidity associated with traditional open surgical approaches.


Subject(s)
Adenocarcinoma/surgery , Breast Neoplasms/pathology , Minimally Invasive Surgical Procedures/methods , Neurosurgical Procedures/methods , Occipital Bone/surgery , Skull Neoplasms/surgery , Adenocarcinoma/complications , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/secondary , Adult , Biopsy/methods , Female , Headache/etiology , Humans , Hypoglossal Nerve Diseases/etiology , Magnetic Resonance Imaging , Occipital Bone/diagnostic imaging , Skull Neoplasms/complications , Skull Neoplasms/diagnostic imaging , Skull Neoplasms/secondary
13.
Med Hypotheses ; 136: 109479, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31778890

ABSTRACT

Although frequently disseminated to other anatomical sites, neuroblastoma (NB) is rarely reported as involving the central nervous system (CNS), which may reflect insufficient research in poorly controlled systemic disease. Here we demonstrate the involvement of the CNS in patients with NB over 18 months of age at diagnosis of extensive systemic disease. Meningeal metastases were observed even in the presence of complete systemic control. Although no improvement in patient's survival was observed, radiotherapy was effective in preventing CNS recurrence after observation of actual or previous dural disease. In conclusion, this study uncovered the uncommon pathologic involvement of the CNS in children with advanced NB and underscores the meningeal surface as a potential pathway for this to occur.


Subject(s)
Central Nervous System/physiopathology , Neoplasm Recurrence, Local/prevention & control , Neuroblastoma/pathology , Neuroblastoma/radiotherapy , Skull Neoplasms/prevention & control , Child, Preschool , Humans , Infant , Meningeal Neoplasms/diagnosis , Meningeal Neoplasms/secondary , Neoplasm Metastasis , Prospective Studies , Radiotherapy , Skull Neoplasms/secondary , Treatment Outcome
14.
World Neurosurg ; 134: e559-e565, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31678450

ABSTRACT

BACKGROUND: Prostate carcinomas rarely metastasize to the central nervous system but, when they do, dural localizations are as common as and far more aggressive than intraparenchymal ones. Those metastases can be further classified according to their extension toward the subdural or extradural space and can frequently simulate other pathologic conditions including chronic subdural hematomas, abscess, and primary bone tumors. Beside the challenges of the preoperative differential diagnostic and complexity of surgical planning and operative excision, subdural metastases seem to carry a much poorer prognosis. METHODS: A series of consecutive patients admitted during a 12-year period through our oncall pathway for subdural/extradural collections or intraparenchymal lesions found, on histologic analysis, to represent intracranial prostate cancer metastases was retrospectively reviewed. RESULTS: A total of 19 patients were included, but only 3 were diagnosed with small cell prostate carcinoma, while the majority had a primary prostate adenocarcinoma. Metastases could be classified as pure subdural space lesions, dural-based lesions, extradural/bony lesions, and pure intraparenchymal lesions. All patients with subdural metastases and 3 out of 5 patients with dural-based lesions required an emergency intervention due to rapidly deteriorating neurologic status. The mean follow-up in our series was 37 months; only subdural localizations had a remarkably unfavorable outcome. CONCLUSIONS: Supported by our experience and the review of the literature, we suggest that a low threshold for contrast-enhanced computed tomography/magnetic resonance imaging is advisable in case of suspicious subdural collection, even in an emergency setting, for patients with previous medical history of prostate cancer.


Subject(s)
Brain Neoplasms/secondary , Carcinoma/pathology , Meningeal Neoplasms/secondary , Prostatic Neoplasms/pathology , Aged , Brain Neoplasms/classification , Brain Neoplasms/diagnosis , Brain Neoplasms/therapy , Carcinoma/classification , Carcinoma/diagnosis , Carcinoma/therapy , Disease Management , Humans , Male , Meningeal Neoplasms/classification , Meningeal Neoplasms/diagnosis , Meningeal Neoplasms/therapy , Middle Aged , Prognosis , Prospective Studies , Prostatic Neoplasms/classification , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/therapy , Retrospective Studies , Skull Neoplasms/classification , Skull Neoplasms/diagnosis , Skull Neoplasms/secondary , Skull Neoplasms/therapy
15.
Medicine (Baltimore) ; 98(49): e18291, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31804374

ABSTRACT

RATIONALE: Intrahepatic cholangiocarcinoma (ICC) originates from the epithelial cells of the secondary branches that are distant from the intrahepatic bile duct. ICC is a rare pathological type of primary liver cancer, with a high malignancy rate and poor prognosis. However, patients with ICC metastasis to the skull are extremely rarely encountered. Herein, we present a case of a metastatic skull tumor from ICC, along with a literature review. PATIENT CONCERNS: A 50-year-old right-handed man who did not smoke was diagnosed with a poorly differentiated ICC (T2aN0M0) in segment VI of the liver in February 2017. Hepatectomy was performed. The patient then presented with a painful mass in the posterior occipital region with dizziness experienced since 1 month, for which he underwent posterior occipital craniotomy. Postoperative specimens were sent for pathological examination. DIAGNOSES: We diagnosed the patient with a metastatic skull tumor from ICC. INTERVENTIONS: The patient underwent posterior occipital craniotomy and total resection of the tumor. OUTCOMES: The patient received chemotherapy 1 month after surgery, and after 6 months of follow-up, the patient was alive. LESSONS: ICC often shows metastases to the vertebrae. Therefore, physicians should consider the possibility of metastasis in patients with ICC, especially in those who show a painful skull mass of unknown origin; moreover, among patients with vertebral metastasis, physicians should be very vigilant about an occipital mass. We believe that the craniospinal venous system may be the pathway for occipital metastasis in patients with ICC.


Subject(s)
Cholangiocarcinoma/pathology , Skull Neoplasms/secondary , Chemotherapy, Adjuvant , Cholangiocarcinoma/surgery , Craniotomy , Hepatectomy , Humans , Male , Middle Aged , Skull Neoplasms/surgery
17.
J Neuropathol Exp Neurol ; 78(12): 1171-1173, 2019 12 01.
Article in English | MEDLINE | ID: mdl-31665371

ABSTRACT

Giant cell tumor (GCT) of bone is a locally aggressive tumor with low metastatic potential, usually originating in long bones. Numerous spinal examples have been reported and thus GCTs can be encountered by neuropathologists. We describe a 69-year-old man with more than a 10-year history of GCT primary to the femur that had recently metastasized to the occipital skull bone. The patient had been receiving denosumab, an adjuvant therapy for GCT, prior to the metastasis. Review of the histological features of the original primary tumor in the femur showed archetypal features of GCT, but the posttreatment occipital skull metastasis showed a predominantly low-to-medium cell density spindle cell tumor with complete depletion of osteoclastic giant cells. Although this effect of the drug is increasingly being recognized by soft tissue pathologists, the current case illustrates the potentially confusing histology of postdenosumab-treated GCT for neuropathologists. The absence of giant cells leads the posttherapy primary or metastatic lesion to show histologic similarity to a multitude of benign and malignant fibro-osseous lesions or spindle cell sarcoma and highlights the importance of eliciting appropriate clinical history.


Subject(s)
Bone Density Conservation Agents/adverse effects , Bone Neoplasms/pathology , Denosumab/adverse effects , Giant Cell Tumor of Bone/pathology , Skull Neoplasms/pathology , Aged , Femur/pathology , Humans , Male , Occipital Bone/pathology , Skull Neoplasms/secondary
18.
Cancer Invest ; 37(9): 501-505, 2019.
Article in English | MEDLINE | ID: mdl-31583922

ABSTRACT

Leptomeningeal metastasis (LM) in solid tumors are rare, even more in renal cell carcinoma (RCC). To date there is a lack of consensual treatment modalities of leptomeningeal metastasis. Furthermore, with the improvement of outcomes and more effective systemic targeted therapies, the management of leptomeningeal metastasis becomes a real challenge. We here report two cases of RCC with leptomeningeal metastasis at initial diagnosis. Both patients had concurrent adjacent skull bone metastasis. Therapeutic management of both patients consisted in surgical resection, followed by radiotherapy in one case. Systemic treatment was delayed according to current recommendations for the management of metastatic RCC. The aim of this work is to report the therapeutic approach and related outcomes and also provide a review of the currently available literature on leptomeningeal disease in renal cell carcinoma. Indeed, local treatment with curative outcome of meningeal location in RCC should be performed specially in LM at initial diagnosis.


Subject(s)
Carcinoma, Renal Cell/diagnostic imaging , Kidney Neoplasms/diagnostic imaging , Meningeal Neoplasms/secondary , Skull Neoplasms/secondary , Aged , Brain/diagnostic imaging , Brain/pathology , Carcinoma, Renal Cell/drug therapy , Carcinoma, Renal Cell/radiotherapy , Combined Modality Therapy , Humans , Kidney Neoplasms/drug therapy , Kidney Neoplasms/radiotherapy , Male , Meningeal Neoplasms/diagnostic imaging , Meningeal Neoplasms/radiotherapy , Meningeal Neoplasms/surgery , Middle Aged , Skull Neoplasms/radiotherapy , Skull Neoplasms/surgery , Sunitinib/therapeutic use , Treatment Outcome
19.
J Pak Med Assoc ; 69(10): 1572-1573, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31622322

ABSTRACT

Prostate cancer (PC) is the second most common malignancy in men. According to International agency for research on cancer,4552 new cases of PC were registered in 2018 in Pakistan.Although majority of cases are confined to prostate on initial presentation, there is a high tendency for advanced PC to metastasize to bone. Metastatic lesions are typically osteoblastic rather than osteolytic. Therefore, these are easily identified by Technetium labeled Methylene Diphosphonate (Tc99m-MDP) uptake on Whole body Bone Scan (BS). Hybrid scanning offers anatomic details for differentiation between aggressive or non-aggressive lesions. Most common axial sites include pelvic bones and spine. Metastases to appendicular skeleton is rare and uncommon . We present a case of 62-years-old male with PC. Follow-up WBS, showed interval development of multiple sites of skeletal metastases. SPECT-CT scan acquired for characterization of atypical site of abnormal MDP uptake in appendicular skeleton, which showed features suggesting skeletal metastasis.


Subject(s)
Adenocarcinoma/diagnostic imaging , Bone Neoplasms/diagnostic imaging , Fibula/diagnostic imaging , Prostatic Neoplasms/pathology , Adenocarcinoma/secondary , Bone Neoplasms/secondary , Humans , Ilium/diagnostic imaging , Male , Middle Aged , Radionuclide Imaging , Radiopharmaceuticals , Single Photon Emission Computed Tomography Computed Tomography , Skull Neoplasms/diagnostic imaging , Skull Neoplasms/secondary , Spinal Neoplasms/diagnostic imaging , Spinal Neoplasms/secondary , Technetium Tc 99m Medronate
20.
Klin Onkol ; 32(4): 300-302, 2019.
Article in English | MEDLINE | ID: mdl-31426647

ABSTRACT

INTRODUCTION: Bone metastasis is seen in 2.3-12.7% of thyroid follicular carcinomas. Bone metastasis most commonly occurs in the vertebrae, costas and hip bones. In this report we discuss the diagnosis and treatment of a patient followed up due to skull metastasis of thyroid follicular carcinoma in light of literature. CASE REPORT: A 51-year-old female patient underwent surgery due a mass in the scalp. The histopathological examination was reported as metastasis of follicular thyroid carcinoma. No radiotherapy was indicated because of the total excision of the mass and the benign surgical margins. The patient, in whom fine needle aspiration biopsy showed the result of follicular carcinoma underwent a total bilateral thyroidectomy. Whole-body I-131 scintigraphy revealed diffuse activity involvement in the thyroid gland, and lung and bone (skull, sacrum, right acetabulum) metastasis. The patient was scheduled for radioactive iodine therapy. CONCLUSION: Total/near total thyroidectomy and metastasectomy should be the treatment of choice in skull metastasis. Postoperative radioactive iodine and radiotherapy should be offered. Radiotherapy should be reserved for inoperable and residual tumour cases.


Subject(s)
Adenocarcinoma, Follicular/pathology , Skull Neoplasms/radiotherapy , Skull Neoplasms/secondary , Thyroid Neoplasms/pathology , Adenocarcinoma, Follicular/surgery , Biopsy, Fine-Needle , Female , Humans , Iodine Radioisotopes , Magnetic Resonance Imaging , Middle Aged , Radiotherapy/methods , Skull Neoplasms/diagnostic imaging , Thyroid Neoplasms/surgery , Thyroidectomy , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...